Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Atherosclerosis ; 201(1): 43-52, 2008 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-18374339

RESUMEN

Studies of the effects of estrogen replacement therapy on coronary heart disease risk have produced conflicting results. We hypothesize that this may be explained by differences in the length of estrogen deficiency prior to initiation of treatment and associated variation in plaque inflammation or stage of progression. The goal of this study was to determine whether estrogen administered after a period of deficiency affects plaque progression and leukocyte populations. Ovariectomized ApoE-/- mice were treated as follows: group 1: continuous estrogen for 90 days (E+/+); group 2: placebo for 45 days followed by estrogen for 45 days (E-/+); group 3: estrogen for 45 days followed by placebo for 45 days (E+/-); and group 4: placebo for 90 days (E-/-). Serum lipoprotein concentrations, plaque size and inflammatory cell (macrophage, CD3+, CD4+, CD8+, dendritic cell, and NK cell) densities were quantified. Plaque size was smaller in groups receiving early estrogen therapy. CD3+ and total inflammatory cell densities were lower in late estrogen therapy groups. The CD8 to dendritic cell ratio was significantly lower in the E-/+ group only. These results suggest that a period of estrogen deficiency followed by reintroduction alters the immunologic environment of atherosclerotic lesions as well as plaque progression.


Asunto(s)
Apolipoproteínas E/fisiología , Aterosclerosis/sangre , Aterosclerosis/patología , Estradiol/administración & dosificación , Terapia de Reemplazo de Estrógeno , Estrógenos/administración & dosificación , Animales , Aterosclerosis/etiología , Esquema de Medicación , Femenino , Recuento de Leucocitos , Ratones , Ratones Endogámicos C57BL , Ovariectomía
2.
J Clin Invest ; 117(10): 2983-92, 2007 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17885686

RESUMEN

Accumulation of cholesteryl esters (CEs) in macrophage foam cells, central to atherosclerotic plaque formation, occurs as a result of imbalance between the cholesterol influx and efflux pathways. While the uptake, or influx, of modified lipoproteins is largely unregulated, extracellular acceptor-mediated free cholesterol (FC) efflux is rate limited by the intracellular hydrolysis of CE. We previously identified and cloned a neutral CE hydrolase (CEH) from human macrophages and demonstrated its role in cellular CE mobilization. In the present study, we examined the hypothesis that macrophage-specific overexpression of CEH in atherosclerosis-susceptible Ldlr(-/-) mice will result in reduction of diet-induced atherosclerosis. Transgenic mice overexpressing this CEH specifically in the macrophages (driven by scavenger receptor promoter/enhancer) were developed and crossed into the Ldlr(-/-) background (Ldlr(-/-)CEHTg mice). Macrophage-specific overexpression of CEH led to a significant reduction in the lesion area and cholesterol content of high-fat, high-cholesterol diet-induced atherosclerotic lesions. The lesions from Ldlr(-/-)CEHTg mice did not have increased FC, were less necrotic, and contained significantly higher numbers of viable macrophage foam cells. Higher CEH-mediated FC efflux resulted in enhanced flux of FC from macrophages to gall bladder bile and feces in vivo. These studies demonstrate that by enhancing cholesterol efflux and reverse cholesterol transport, macrophage-specific overexpression of CEH is antiatherogenic.


Asunto(s)
Aterosclerosis/patología , Ésteres del Colesterol/metabolismo , Macrófagos Peritoneales/enzimología , Esterol Esterasa/metabolismo , Animales , Aorta/patología , Aterosclerosis/genética , Colesterol/sangre , Colesterol/metabolismo , Expresión Génica , Humanos , Ratones , Ratones Transgénicos , Necrosis/patología , Receptores de LDL/genética , Esterol Esterasa/genética
3.
Am J Physiol Cell Physiol ; 292(1): C405-12, 2007 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-16971496

RESUMEN

Reduction of the lipid burden of atherosclerotic lesion-associated macrophage foam cells is a logical strategy to reduce the plaque volume. Since extracellular cholesterol acceptor-mediated cholesterol efflux is the only recognized mechanism of cholesterol removal from foam cells and this process is rate limited at the level of intracellular cholesterol ester hydrolysis, a reaction catalyzed by neutral cholesteryl ester hydrolase (CEH), we examined the hypothesis that CEH overexpression in the human macrophage monocyte/macrophage cell line THP1 results in increased cholesterol efflux, as well as decreased cellular cholesterol ester accumulation. We generated THP1-CEH cells with stable integration of human macrophage CEH cDNA driven by the cytomegalovirus promoter. Compared with wild-type THP1 cells (THP1-WT), THP1-CEH cells showed increased CEH mRNA expression and increased CEH activity. Efflux of free or unesterified cholesterol by acetylated LDL-loaded THP1-CEH cells to ApoA-I by an ABCA1-dependent pathway or to HDL by an ABCG1-dependent pathway was significantly higher than that in THP1-WT cells. In addition, THP1-CEH cells accumulated significantly lower amount of esterified cholesterol. CEH overexpression, therefore, not only enhances cholesterol efflux but also reduces cellular accumulation of cholesteryl esters. Taken together, these data provide evidence for evaluating CEH expression in human macrophages as a potential target for attenuation of foam cell formation and regression of atherosclerotic plaques.


Asunto(s)
Colesterol/metabolismo , Macrófagos/metabolismo , Esterol Esterasa/metabolismo , Apolipoproteína A-I/farmacología , Sangre , Línea Celular , Ésteres del Colesterol/metabolismo , Expresión Génica , Humanos , Lipoproteínas HDL/farmacología , Lipoproteínas LDL/farmacología , Macrófagos/enzimología , ARN Mensajero/metabolismo , Esterol Esterasa/genética
4.
J Lipid Res ; 46(10): 2114-21, 2005 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16024911

RESUMEN

Hydrolysis of intracellular cholesteryl esters (CEs) represents the first step in the removal of cholesterol from lipid-laden foam cells associated with atherosclerotic lesions. Neutral cholesteryl ester hydrolase (CEH) catalyzes this reaction, and we recently cloned the cDNA for the human macrophage CEH and demonstrated increased mobilization of intracellular CE droplets by CEH overexpression. The present study was undertaken to test the hypothesis that for CE hydrolysis, CEH must become associated with the surface of the cytoplasmic lipid droplets. Our data show the redistribution of CEH from cytosol to lipid droplets upon lipid loading of human THP-1 macrophages. Depletion of triacylglycerol (TG) by incubation with the acyl-CoA synthetase inhibitor Triacsin D had no effect on CEH association with the lipid droplets, suggesting that CEH associates with mixed (CE + TG) as well as TG-depleted CE droplets. However, CEH had 2.5-fold higher activity when mixed droplets were used as substrate in an in vitro assay, consistent with the reported higher cholesterol efflux from cells containing mixed isotropic droplets. Perilipin as well as adipophilin, two lipid droplet-associated proteins, were also present on the lipid droplets in THP-1 macrophages. In conclusion, CEH associates with its intracellular substrate (lipid droplets) and hydrolyzes CE more efficiently from mixed droplets.


Asunto(s)
Citoplasma/enzimología , Macrófagos/enzimología , Esterol Esterasa/metabolismo , Western Blotting , Proteínas Portadoras , Línea Celular , Ésteres del Colesterol/metabolismo , Coenzima A Ligasas/antagonistas & inhibidores , Citosol/enzimología , Humanos , Lipoproteínas LDL/farmacología , Proteínas de la Membrana , Péptidos/metabolismo , Perilipina-1 , Perilipina-2 , Fosfoproteínas/metabolismo , Triazenos/farmacología , Triglicéridos/metabolismo
5.
Atherosclerosis ; 170(1): 31-8, 2003 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-12957680

RESUMEN

The efflux of cholesterol from cells and its incorporation into HDL is believed to be the initial step in reverse cholesterol transport. This report addresses the question of whether there is a relationship between the ability of serum to promote efflux of cholesterol from cells in culture and the severity of coronary artery atherosclerosis (CAA). Surgically postmenopausal cynomolgus monkeys (n=142) were treated for 2-years with conjugated equine estrogens (CEE), CEE plus medroxyprogesterone acetate, or two different doses of tibolone, a synthetic steroid. CAA was determined at necropsy, and the cholesterol efflux potential of serum from each animal was determined using 3H-cholesterol-labeled Fu5AH cells and human skin fibroblasts in culture. A significant negative correlation was seen between CAA and cholesterol efflux from Fu5AH cells (r=-0.44, P< or =0.0001), but not skin fibroblasts. Although there was a wide range of plasma HDL cholesterol concentrations in these animals (10-81 mg/dl), using multiple regression analysis, LDL+VLDL cholesterol and the serum cholesterol efflux potential were the only significant independent predictors of CAA, explaining 41.6 and 10.7% of the variability (P<0.0001), respectively. Thus, the potential of serum to promote cholesterol efflux from Fu5AH cells may represent a useful independent measure for improving the assessment of CAA risk.


Asunto(s)
Colesterol/sangre , Enfermedad de la Arteria Coronaria/sangre , Animales , Apolipoproteína A-I/sangre , Apolipoproteína A-I/efectos de los fármacos , Arterias/efectos de los fármacos , Arterias/metabolismo , Arterias/patología , Biomarcadores/sangre , HDL-Colesterol/sangre , HDL-Colesterol/efectos de los fármacos , LDL-Colesterol/sangre , LDL-Colesterol/efectos de los fármacos , VLDL-Colesterol/sangre , VLDL-Colesterol/efectos de los fármacos , Vasos Coronarios/efectos de los fármacos , Vasos Coronarios/metabolismo , Vasos Coronarios/patología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Moduladores de los Receptores de Estrógeno/administración & dosificación , Femenino , Fibroblastos/efectos de los fármacos , Fibroblastos/metabolismo , Haplorrinos , Modelos Cardiovasculares , Análisis Multivariante , Norpregnenos/administración & dosificación , Variaciones Dependientes del Observador , Valor Predictivo de las Pruebas , Piel/citología , Piel/efectos de los fármacos , Piel/metabolismo , Estadística como Asunto , Túnica Íntima/efectos de los fármacos , Túnica Íntima/metabolismo , Túnica Íntima/patología , Salud de la Mujer
6.
J Lipid Res ; 44(10): 1833-40, 2003 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-12837853

RESUMEN

The obligatory first step in the removal of cholesterol from foam cells is the hydrolysis of stored cholesteryl esters (CEs) to release free cholesterol (FC). Neutral cholesteryl ester hydrolase (CEH) catalyzes this hydrolysis, and limiting levels of CEH could play a role in determining the susceptibility to atherosclerosis. We have recently reported the first identification and cloning of cDNA for human macrophage CEH. In the present study, we tested the hypothesis that systematically varied levels of overexpression of human macrophage CEH results in a proportional degree of reduction in cellular CE content in a cell system with known and reproducible amounts of CE accumulation. CEH expression was confirmed by demonstrating the presence of CEH mRNA and protein with an increase in CEH activity. A significant reduction in intracellular lipid droplets was observed in CEH-expressing cells, together with a decrease in cellular CE mass and a 2-fold increase in FC efflux. These results demonstrate that when human macrophage CEH is expressed in lipid-laden cells, hydrolysis and mobilization of CE (stored as lipid droplets) occur. These data establish the possibility that increased CE hydrolysis, mediated by CEH up-regulation, could represent an important mechanism to reduce the cholesterol burden of foam cells.


Asunto(s)
Ésteres del Colesterol/metabolismo , Citoplasma/metabolismo , Macrófagos/metabolismo , Esterol Esterasa/metabolismo , Arteriosclerosis/metabolismo , Células Cultivadas , ADN Complementario/metabolismo , Células Espumosas/metabolismo , Expresión Génica , Humanos , Hidrólisis , Inmunohistoquímica , ARN Mensajero/metabolismo , Factores de Tiempo , Transfección
7.
J Lipid Res ; 44(4): 770-9, 2003 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-12562836

RESUMEN

LDL enriched with either saturated, monounsaturated, n-6 polyunsaturated, or n-3 polyunsaturated fatty acids were used to study the effects of dietary fatty acids on macrophage cholesteryl ester (CE) accumulation, physical state, hydrolysis, and cholesterol efflux. Incubation of THP-1 macrophages with acetylated LDL (AcLDL) from each of the four diet groups resulted in both CE and triglyceride (TG) accumulation, in addition to alterations of cellular CE, TG, and phospholipid fatty acyl compositions reflective of the individual LDLs. Incubation with monounsaturated LDL resulted in significantly higher total and CE accumulation when compared with the other groups. After TG depletion, intracellular anisotropic lipid droplets were visible in all four groups, with 71% of the cells incubated with monounsaturated AcLDL containing anisotropic lipid droplets, compared with 30% of cells incubated with n-3 AcLDL. These physical state differences translated into higher rates of both CE hydrolysis and cholesterol efflux in the n-3 group. These data suggest that monounsaturated fatty acids may enhance atherosclerosis by increasing both cholesterol delivery to macrophage foam cells and the percentage of anisotropic lipid droplets, while n-3 PUFAs decrease atherosclerosis by creating more fluid cellular CE droplets that accelerate the rate of CE hydrolysis and the efflux of cholesterol from the cell.


Asunto(s)
Ésteres del Colesterol/metabolismo , Dieta , Ácidos Grasos/farmacología , Lipoproteínas LDL/farmacología , Macrófagos/metabolismo , Animales , Arteriosclerosis/etiología , Línea Celular , Chlorocebus aethiops , Colesterol/metabolismo , Ácidos Grasos Omega-3 , Humanos , Hidrólisis/efectos de los fármacos , Metabolismo de los Lípidos , Triglicéridos/metabolismo
8.
Stroke ; 33(11): 2700-3, 2002 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-12411664

RESUMEN

BACKGROUND AND PURPOSE: Tibolone is a tissue-specific compound that has favorable effects on bone and menopausal symptoms without stimulating endometrium or breast, but lowers concentrations of plasma high-density lipoprotein (HDL) cholesterol (HDLC). This study was designed to determine whether the HDL lowering with tibolone exacerbated common or internal carotid artery atherosclerosis and to evaluate tibolone treatment relative to conjugated equine estrogens (CEE) alone or in combination with medroxyprogesterone acetate (MPA). METHODS: Carotid artery atherosclerosis was compared in groups of surgically postmenopausal cynomolgus monkeys treated with CEE, CEE+MPA, or either of 2 doses of tibolone versus untreated monkeys. RESULTS: Despite a 30% to 52% lowering of HDLC with tibolone, there was no significant effect on carotid artery atherosclerosis. CEE and CEE+MPA, however, inhibited carotid artery atherosclerosis by approximately 60%. CONCLUSIONS: In surgically postmenopausal cynomolgus monkeys, CEE and CEE+MPA inhibited common and internal carotid artery atherosclerosis. Despite the potentially adverse effects of tibolone on HDLC, tibolone did not exacerbate atherosclerosis.


Asunto(s)
Enfermedades de las Arterias Carótidas/prevención & control , Moduladores de los Receptores de Estrógeno/uso terapéutico , Estrógenos Conjugados (USP)/uso terapéutico , Norpregnenos/farmacología , Posmenopausia/efectos de los fármacos , Animales , Enfermedades de las Arterias Carótidas/sangre , Enfermedades de las Arterias Carótidas/patología , Arteria Carótida Común/efectos de los fármacos , Arteria Carótida Común/patología , Arteria Carótida Interna/efectos de los fármacos , Arteria Carótida Interna/patología , HDL-Colesterol/sangre , HDL-Colesterol/efectos de los fármacos , VLDL-Colesterol/sangre , Dieta Aterogénica , Modelos Animales de Enfermedad , Progresión de la Enfermedad , Quimioterapia Combinada , Terapia de Reemplazo de Estrógeno , Femenino , Lipoproteínas LDL/sangre , Macaca fascicularis , Acetato de Medroxiprogesterona/uso terapéutico , Posmenopausia/sangre , Tiempo , Grado de Desobstrucción Vascular/efectos de los fármacos
9.
Maturitas ; 41(4): 313-9, 2002 Apr 25.
Artículo en Inglés | MEDLINE | ID: mdl-12034518

RESUMEN

OBJECTIVE: To investigate the effect of 17beta-estradiol (E2) on binding of monocytes to human aortic endothelial cells (HAECs) with or without cytokine induction. METHODS: Confluent monolayers of HAECs were incubated with or without E2 for 48 h prior to the monocyte adhesion assay. In studies with cytokines, 1 ng/ml tumor necrosis factor-alpha (TNF-alpha), 20 U/ml interleukin-1beta (IL-1beta) or both were added to the culture medium for the final 24 or 4 h. For the measurement of monocyte adhesion, 3H-thymidine labeled human THP-1 monocytes (4 x 10(5) cells per well) were added to the confluent monolayer of HAECs and incubated at 37 degrees C for 90 min. The unbound THP-1 cells were removed by gentle washing, and bound cells were digested with NaOH and quantified by measuring radioactivity. RESULTS: When HAECs were pretreated for 48 h with E2 the basal adhesion of THP-1 cells was reduced by an average of 28%. Estrogen significantly reduced cytokine-induced adhesion by 30-35% when the cytokines were added for 4 h. When the cytokine treatment was prolonged to 24 h, pretreatment of HAECs with E2 had no effect on THP-1 cell adhesion. CONCLUSIONS: E2 reduces basal and short-term cytokine induced monocyte binding to HAECs. Since monocyte adhesion to vascular endothelial cells is one of the initial steps in the pathogenesis of atherosclerosis, E2 may mediate vascular protection by reducing monocyte-endothelial cell binding in the early stages of atherogenesis.


Asunto(s)
Endotelio Vascular/citología , Estradiol/farmacología , Monocitos/fisiología , Adhesión Celular , Células Cultivadas , Citocinas/farmacología , Femenino , Humanos
10.
Metabolism ; 51(4): 523-30, 2002 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-11912565

RESUMEN

Tibolone is a synthetic steroid used for the treatment of climacteric symptoms and the prevention of osteoporosis, but the effect on the cardiovascular system is unclear since tibolone lowers high-density lipoprotein (HDL) levels. We investigated if long-term treatment with tibolone or conventional hormone replacement therapy (HRT) in cynomolgus monkeys could affect their serum cholesterol efflux potential. Surgically postmenopausal cynomolgus monkeys were treated for 2 years with conjugated equine estrogens (CEE), CEE plus medroxyprogesterone acetate (MPA), low-dose tibolone, or high-dose tibolone. Plasma lipid, lipoprotein, and apolipoprotein levels were monitored during the study. The cholesterol efflux potential of the serum from each animal was determined in (3)H-cholesterol-labeled Fu5AH cells and skin fibroblasts in culture. Tibolone induced a dose-dependent 30% to 52% reduction in HDL levels. When HDL concentrations were reduced by 30%, as seen in women, there was no reduction in the serum cholesterol efflux potential in Fu5AH cells. With a 52% reduction in HDL, there was a 14% reduction in cholesterol efflux. Although CEE or CEE+MPA had no significant effect on HDL levels, CEE treatment increased serum cholesterol efflux potential by 7%. With the same sera, no changes in cholesterol efflux were seen with fibroblasts. Although our findings suggest that HDL concentration is correlated with cholesterol efflux potential of serum, this relationship is weak, explaining only 16% of the variability. This is emphasized by the fact that despite a 30% lowering of HDL with tibolone, there was no indication of an adverse effect on cellular cholesterol efflux. Other changes in the serum not measured in this study must contribute significantly to the cholesterol efflux potential of serum. Because changes in cholesterol efflux potential of serum were seen only in Fu5AH cells, a cell line rich in SR-B1 receptors, this implies that the changes seen in this study were mediated largely by the SR-B1 pathway.


Asunto(s)
Colesterol/sangre , Moduladores de los Receptores de Estrógeno/farmacología , Estrógenos Conjugados (USP)/farmacología , Norpregnenos/farmacología , Ovariectomía , Análisis de Varianza , Animales , Apolipoproteínas/sangre , Línea Celular , HDL-Colesterol/sangre , LDL-Colesterol/sangre , Femenino , Caballos , Macaca fascicularis , Análisis de Regresión , Triglicéridos/sangre
11.
J Lipid Res ; 43(4): 618-28, 2002 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-11907145

RESUMEN

To study macrophage lipid droplet composition and the effects of TG on cholesteryl ester (CE) physical state, hydrolysis, and cholesterol efflux, a technique was developed to remove the majority of accumulated TG with minimal effect on CE content. THP-1 macrophages were incubated with acetylated LDL, and the accumulated TG was depleted by incubation with the acyl-CoA synthetase inhibitor triacsin D in the presence of albumin. Before TG removal, all cellular lipid droplets were isotropic as determined by polarizing light microscopy. When the TG concentration was reduced, anisotropic lipid droplets were visible, indicating a change in physical state, and suggesting that TG and CE originally accumulated in mixed lipid droplets. This change in physical state of lipid droplets was associated with slower rates of CE hydrolysis and cholesterol efflux. Although lipid droplets within the same cell had a similar physical state after TG depletion, there was considerable variability among cells in the physical state of their lipid droplets. In conclusion, THP-1 macrophages store accumulated CE and TG in mixed droplets, and the proportion of CE to TG varies among cells. Reducing accumulated TG altered CE physical state, which in turn affected hydrolysis of CE and cholesterol efflux.


Asunto(s)
Ésteres del Colesterol/química , Colesterol/metabolismo , Lípidos/química , Macrófagos/metabolismo , Triglicéridos/metabolismo , Acetato CoA Ligasa/antagonistas & inhibidores , Transporte Biológico , Células Cultivadas , Ésteres del Colesterol/metabolismo , Inhibidores Enzimáticos/farmacología , Humanos , Hidrólisis , Macrófagos/química , Macrófagos/efectos de los fármacos , Tamaño de la Partícula , Triazenos/farmacología , Triglicéridos/química , Triglicéridos/deficiencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...